Nyxoah S.A.

Europe's biotechs have always held their own when it comes to scientific innovation but despite the tricky climate for financing, there are plenty of firms that have the potential to go from discovery

Nyxoah S.A. is taking to the stock market to raise around €60m ($71m) to fund further development of its Genio implantable neurostimulation system for treating obstructive sleep apnea (OSA). Around h

ResMed Inc. , the market leader in continuous positive airway pressure (CPAP) for sleep apnea, has invested €9m ($11.7m) in Nyxoah SA as part of a €25m ($32.6m) funding round by the Belgian company.

Obstructive sleep apnea (OSA) is a common, devastating and costly condition. It affects an estimated 100 million people worldwide, of whom 18 million are in the US alone, and its societal costs are hu